newsfilter
← Latest News
Business Wire·

ImmunoPrecise Advances AI Discovered and Developed Universal Dengue Vaccine Initiative: Moves into Preclinical Antibody Generation

Manufacturing of validated dengue epitope underway; proprietary immunization studies in rabbit model to assess monoclonal antibody (mAb) responses. ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"),